RxDoctor Payments Data

Amrittej Virk

Orofacial Pain · Southlake, TXNPI 1346732153

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,139 of the $3,339 with a category attached, or 64.1%. 7 manufacturers reported payments, led by Biohaven Pharmaceutical Holding Company Ltd. at 50.4% of the total. Reporting peaked in 2022 at $1,765 and has fallen 81.6% since, to $325 in 2025.

$3,339in general payments, 2019–2025

Across 107 payments — averaging $31.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Pfizer$734
  • AbbVie$558
  • Biohaven Pharmaceuticals, Inc.$182
  • Dentsply Sirona Inc$148
  • Patterson Companies, Inc.$18
  • plus $15 from 1 others

What the payments were for

  • Consulting fees$1,20036%
  • Food & beverage$2,13964%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few orofacial pain providers in Texasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$149,038
Medicare patients
170
Services billed
2,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin25$311
Baclofen12$245
Amitriptyline Hcl13$144

Paid to pharmacies, not to this prescriber.

Other orofacial pain in Southlake

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →